Analysts Are Bullish on These Healthcare Stocks: Alnylam Pharma (ALNY), Sysmex (SSMXF)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alnylam Pharma (ALNY – Research Report), Sysmex (SSMXF – Research Report) and Vertex Pharmaceuticals (VRTX – Research Report) with bullish sentiments.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Alnylam Pharma (ALNY)
In a report released yesterday, William Pickering from Bernstein maintained a Buy rating on Alnylam Pharma, with a price target of $491.00. The company’s shares closed last Thursday at $308.48.
According to TipRanks.com, Pickering is a 3-star analyst with an average return of
Alnylam Pharma has an analyst consensus of Strong Buy, with a price target consensus of $470.00, a 49.5% upside from current levels. In a report issued on January 29, TD Cowen also maintained a Buy rating on the stock with a $482.00 price target.
See today’s best-performing stocks on TipRanks >>
Sysmex (SSMXF)
In a report released today, Akinori Ueda from Goldman Sachs maintained a Buy rating on Sysmex, with a price target of Yen2000.00. The company’s shares closed last Friday at $9.88.
According to TipRanks.com, Ueda is a 3-star analyst with an average return of
Sysmex has an analyst consensus of Moderate Buy, with a price target consensus of $14.36.
Vertex Pharmaceuticals (VRTX)
In a report issued on February 11, Salveen Richter from Goldman Sachs maintained a Buy rating on Vertex Pharmaceuticals, with a price target of $625.00. The company’s shares closed last Thursday at $465.02.
According to TipRanks.com, Richter is a 4-star analyst with an average return of
Currently, the analyst consensus on Vertex Pharmaceuticals is a Strong Buy with an average price target of $546.30, which is a 18.2% upside from current levels. In a report issued on January 28, Barclays also upgraded the stock to Buy with a $606.00 price target.
